Access the full text.
Sign up today, get DeepDyve free for 14 days.
N. Marx, H. Duez, J. Fruchart, B. Staels (2004)
Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells.Circulation research, 94 9
R. Mukherjee, L. Jow, G. Croston, J. Paterniti (1997)
Identification, Characterization, and Tissue Distribution of Human Peroxisome Proliferator-activated Receptor (PPAR) Isoforms PPARγ2 versus PPARγ1 and Activation with Retinoid X Receptor Agonists and Antagonists*The Journal of Biological Chemistry, 272
Q. Diep, M. Mabrouk, J. Cohn, D. Endemann, F. Amiri, A. Virdis, M. Neves, E. Schiffrin (2002)
Structure, Endothelial Function, Cell Growth, and Inflammation in Blood Vessels of Angiotensin II–Infused Rats: Role of Peroxisome Proliferator–Activated Receptor-&ggr;Circulation: Journal of the American Heart Association, 105
N. Marx, F. Mach, A. Sauty, J. Leung, M. Sarafi, R. Ransohoff, P. Libby, J. Plutzky, A. Luster (2000)
Peroxisome Proliferator-Activated Receptor-γ Activators Inhibit IFN-γ-Induced Expression of the T Cell-Active CXC Chemokines IP-10, Mig, and I-TAC in Human Endothelial Cells1The Journal of Immunology, 164
C. Dreyer, G. Krey, H. Keller, F. Givel, G. Helftenbein, W. Wahli (1992)
Control of the peroxisomal beta-oxidation pathway by a novel family of nuclear hormone receptors.Cell, 68 5
I. Inoue, Kouta Shino, S. Noji, T. Awata, S. Katayamá (1998)
Expression of peroxisome proliferator-activated receptor alpha (PPAR alpha) in primary cultures of human vascular endothelial cells.Biochemical and biophysical research communications, 246 2
P. Puddu, G. Puddu, A. Muscari (2003)
Peroxisome proliferator-activated receptors: are they involved in atherosclerosis progression?International journal of cardiology, 90 2-3
Lucía Gilling, P. Suwattee, C. Desouza, S. Asnani, V. Fonseca (2002)
Effects of the Thiazolidinediones on Cardiovascular Risk FactorsAmerican Journal of Cardiovascular Drugs, 2
M. Schupp, J. Janke, R. Clasen, T. Unger, U. Kintscher (2004)
Angiotensin Type 1 Receptor Blockers Induce Peroxisome Proliferator–Activated Receptor-γ ActivityCirculation: Journal of the American Heart Association, 109
M. Bayés, X. Rabasseda, J. Prous (2006)
Gateways to clinical trials.Methods and findings in experimental and clinical pharmacology, 28 6
J. Plutzky (1999)
Atherosclerotic plaque rupture: emerging insights and opportunities.The American journal of cardiology, 84 1A
D. McDonnell (2000)
Selective estrogen receptor modulators (SERMs): A first step in the development of perfect hormone replacement therapy regimen.Journal of The Society for Gynecologic Investigation, 7
Zhong Chen, S. Ishibashi, S. Perrey, J. Osuga, T. Gotoda, T. Kitamine, Y. Tamura, H. Okazaki, N. Yahagi, Y. Iizuka, F. Shionoiri, K. Ohashi, K. Harada, H. Shimano, R. Nagai, N. Yamada (2001)
Troglitazone Inhibits Atherosclerosis in Apolipoprotein E–Knockout Mice: Pleiotropic Effects on CD36 Expression and HDLArteriosclerosis, Thrombosis, and Vascular Biology: Journal of the American Heart Association, 21
Weimin He, Y. Barak, A. Hevener, P. Olson, D. Liao, J. Le, M. Nelson, E. Ong, J. Olefsky, R. Evans (2003)
Adipose-specific peroxisome proliferator-activated receptor γ knockout causes insulin resistance in fat and liver but not in muscleProceedings of the National Academy of Sciences of the United States of America, 100
L. Tao, Huirong Liu, E. Gao, Z. Teng, B. Lopez, T. Christopher, Xinliang Ma, I. Batinic-Haberle, R. Willette, E. Ohlstein, T. Yue (2003)
Antioxidative, Antinitrative, and Vasculoprotective Effects of a Peroxisome Proliferator–Activated Receptor-&ggr; Agonist in HypercholesterolemiaCirculation: Journal of the American Heart Association, 108
横山 光宏, R. Ross (1998)
Atherosclerosis is an Inflammatory DiseaseJapanese Circulation Journal-english Edition, 62
E.E. Creemers, J.P. Cleutjens, J.F. Smits (2001)
Matrix metalloproteinase inhibition after myocardial infarction: a new approach to prevent heart failure?Circ Res, 89
C. Argmann, C. Sawyez, C. McNeil, R. Hegele, M. Huff (2003)
Activation of Peroxisome Proliferator–Activated Receptor Gamma and Retinoid X Receptor Results in Net Depletion of Cellular Cholesteryl Esters in Macrophages Exposed to Oxidized LipoproteinsArteriosclerosis, Thrombosis, and Vascular Biology: Journal of the American Heart Association, 23
S. Jackson, F. Parhami, X. Xi, J. Berliner, W. Hsueh, R. Law, L. Demer (1999)
Peroxisome proliferator-activated receptor activators target human endothelial cells to inhibit leukocyte-endothelial cell interaction.Arteriosclerosis, thrombosis, and vascular biology, 19 9
T. Ogihara, H. Rakugi, H. Ikegami, H. Mikami, K. Masuo (1995)
Enhancement of insulin sensitivity by troglitazone lowers blood pressure in diabetic hypertensives.American journal of hypertension, 8 3
T. Lüscher, M. Barton (1997)
Biology of the EndotheliumClinical Cardiology, 20
N. Marx, J. Froehlich, L. Siam, J. Ittner, G. Wierse, A. Schmidt, H. Scharnagl, V. Hombach, W. Koenig (2003)
Antidiabetic PPAR&ggr;-Activator Rosiglitazone Reduces MMP-9 Serum Levels in Type 2 Diabetic Patients With Coronary Artery DiseaseArteriosclerosis, Thrombosis, and Vascular Biology: Journal of the American Heart Association, 23
Y. Barak, Michael Nelson, Michael Nelson, E. Ong, E. Ong, Y. Jones, P. Ruiz‐Lozano, K. Chien, A. Koder, R. Evans, R. Evans (1999)
PPARγ Is Required for Placental, Cardiac, and Adipose Tissue DevelopmentMolecular Cell, 4
M. Ricote, Jannet Huang, L. Fajas, A. Li, J. Welch, J. Najib, J. Witztum, J. Auwerx, W. Palinski, C. Glass (1998)
Expression of the peroxisome proliferator-activated receptor γ (PPARγ) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoproteinProceedings of the National Academy of Sciences of the United States of America, 95
S. Haffner, A. Greenberg, W. Weston, Hongzi Chen, K. Williams, M. Freed (2002)
Effect of Rosiglitazone Treatment on Nontraditional Markers of Cardiovascular Disease in Patients With Type 2 Diabetes MellitusCirculation: Journal of the American Heart Association, 106
M. Ishibashi, K. Egashira, K. Hiasa, S. Inoue, W. Ni, Qingwei Zhao, M. Usui, S. Kitamoto, T. Ichiki, A. Takeshita (2002)
Antiinflammatory and Antiarteriosclerotic Effects of PioglitazoneHypertension: Journal of the American Heart Association, 40
B. Neve, J. Fruchart, B. Staels (2000)
Role of the peroxisome proliferator-activated receptors (PPAR) in atherosclerosis.Biochemical pharmacology, 60 8
T. Mazzone (2004)
Strategies in ongoing clinical trials to reduce cardiovascular disease in patients with diabetes mellitus and insulin resistance.The American journal of cardiology, 93 11A
H. Ogita, J. Liao (2004)
Endothelial function and oxidative stress.Endothelium : journal of endothelial cell research, 11 2
M. Gimbrone, N. Resnick, T. Nagel, L. Khachigian, T. Collins, J. Topper (1997)
Hemodynamics, Endothelial Gene Expression, and Atherogenesis aAnnals of the New York Academy of Sciences, 811
E.L. Schiffrin, F. Amiri, K. Benkirane (2003)
Peroxisome proliferator-activated receptors: vascular and cardiac effects in hypertensionHypertension, 42
R. Stocker, J. Keaney (2004)
Role of oxidative modifications in atherosclerosis.Physiological reviews, 84 4
M. Iglarz, R. Touyz, F. Amiri, Marie-France Lavoie, Q. Diep, E. Schiffrin (2003)
Effect of Peroxisome Proliferator–Activated Receptor-&agr; and -&ggr; Activators on Vascular Remodeling in Endothelin-Dependent HypertensionArteriosclerosis, Thrombosis, and Vascular Biology: Journal of the American Heart Association, 23
DE Moller, J. Berger (2003)
Role of PPARs in the regulation of obesity-related insulin sensitivity and inflammationInternational Journal of Obesity, 27
N. Kubota, Y. Terauchi, H. Miki, H. Tamemoto, T. Yamauchi, K. Komeda, S. Satoh, R. Nakano, C. Ishii, T. Sugiyama, K. Eto, Y. Tsubamoto, A. Okuno, K. Murakami, H. Sekihara, G. Hasegawa, M. Naito, Y. Toyoshima, Satoshi Tanaka, K. Shiota, T. Kitamura, T. Fujita, O. Ezaki, S. Aizawa, R. Nagai, K. Tobe, S. Kimura, T. Kadowaki (1999)
PPARγ Mediates High-Fat Diet–Induced Adipocyte Hypertrophy and Insulin ResistanceMolecular Cell, 4
H. Keen, M. Ryan, Andreas Beyer, S. Mathur, T. Scheetz, Barry Gackle, F. Faraci, T. Casavant, C. Sigmund (2004)
Gene expression profiling of potential PPARγ target genes in mouse aortaPhysiological Genomics, 18
S. Wu, L. Ho, H. Li, H. Chiang (2000)
Regulation of Ca(2+)-activated K+ currents by ciglitazone in rat pituitary GH3 cells.Journal of investigative medicine : the official publication of the American Federation for Clinical Research, 48 4
H. Hong, Y. Cho, Kyung-Ho Park, Choon‐Taek Lee, Hong-Kyu Lee, K. Park (2003)
Peroxisome proliferator-activated receptor gamma mediated inhibition of plasminogen activator inhibitor type 1 production and proliferation of human umbilical vein endothelial cells.Diabetes research and clinical practice, 62 1
J. Lehmann, L. Moore, T. Smith-Oliver, W. Wilkison, T. Willson, S. Kliewer (1995)
An Antidiabetic Thiazolidinedione Is a High Affinity Ligand for Peroxisome Proliferator-activated Receptor γ (PPARγ) (*)The Journal of Biological Chemistry, 270
V. Pasceri, V. Pasceri, Henry Wu, J. Willerson, J. Willerson, E. Yeh (2000)
Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-gamma activators.Circulation, 101 3
W. Hsueh, D. Bruemmer (2004)
Peroxisome Proliferator-Activated Receptor &ggr;: Implications for Cardiovascular DiseaseHypertension: Journal of the American Heart Association, 43
D. Savage, M. Agostini, I. Barroso, M. Gurnell, J. Luan, A. Meirhaeghe, A. Harding, G. Ihrke, O. Rajanayagam, M. Soos, Stella George, Dirk Berger, Elizabeth Thomas, Jimmy Bell, K. Meeran, R. Ross, A. Vidal-Puig, N. Wareham, S. O’Rahilly, V. Chatterjee, A. Schafer (2002)
Digenic inheritance of severe insulin resistance in a human pedigreeNature Genetics, 31
J. Sidhu, Z. Káposzta, H. Markus, J. Kaski (2004)
Effect of rosiglitazone on common carotid intima-media thickness progression in coronary artery disease patients without diabetes mellitus.Arteriosclerosis, thrombosis, and vascular biology, 24 5
G. Chinetti, J. Fruchart, B. Staels (2003)
Peroxisome proliferator-activated receptors and inflammation: from basic science to clinical applicationsInternational Journal of Obesity, 27
R. Negro, D. Dazzi, Haslinda Hassan, A. Pezzarossa (2004)
Pioglitazone reduces blood pressure in non-dipping diabetic patients.Minerva endocrinologica, 29 1
I. Barroso, M. Gurnell, V. Crowley, M. Agostini, J. Schwabe, M. Soos, G. Maslen, T. Williams, H. Lewis, A. Schafer, V. Chatterjee, S. O’Rahilly (1999)
Dominant negative mutations in human PPARγ associated with severe insulin resistance, diabetes mellitus and hypertensionNature, 402
H. Yki-Jarvinen (2004)
ThiazolidinedionesN Engl J Med, 351
X.Y. Yang, L.H. Wang, T. Chen (2000)
Activation of human T lymphocytes is inhibited by peroxisome proliferator-activated receptor-β (PPARβ) agonists. PPARβ co-association with transcription factor NFATJ Biol Chem, 275
H. Satoh, K. Tsukamoto, Y. Hashimoto, Naoaki Hashimoto, M. Togo, M. Hara, H. Maekawa, Naoyuki Iso-o, S. Kimura, Tsuyoshi Watanabe (1999)
Thiazolidinediones suppress endothelin-1 secretion from bovine vascular endothelial cells: a new possible role of PPARgamma on vascular endothelial function.Biochemical and biophysical research communications, 254 3
S. Benson, H. Pershadsingh, Christopher Ho, A. Chittiboyina, P. Desai, M. Pravenec, N. Qi, Jiaming Wang, M. Avery, T. Kurtz (2004)
Identification of Telmisartan as a Unique Angiotensin II: Receptor Antagonist With Selective PPARγ–Modulating ActivityHypertension: Journal of the American Heart Association, 43
A. Hevener, Weimin He, Y. Barak, J. Le, G. Bandyopadhyay, P. Olson, J. Wilkes, R. Evans, J. Olefsky (2003)
Muscle-specific Pparg deletion causes insulin resistanceNature Medicine, 9
C. Blanquart, O. Barbier, J. Fruchart, B. Staels, C. Glineur (2003)
Peroxisome proliferator-activated receptors: regulation of transcriptional activities and roles in inflammationThe Journal of Steroid Biochemistry and Molecular Biology, 85
Y. Taniyama, K. Griendling (2003)
Reactive oxygen species in the vasculature: molecular and cellular mechanisms.Hypertension, 42 6
M. Ryan, S. Didion, S. Mathur, F. Faraci, C. Sigmund (2004)
PPAR&ggr; Agonist Rosiglitazone Improves Vascular Function and Lowers Blood Pressure in Hypertensive Transgenic MiceHypertension: Journal of the American Heart Association, 43
D. Cho, Yoon Choi, S. Jo, I. Jo (2004)
Nitric Oxide Production and Regulation of Endothelial Nitric-oxide Synthase Phosphorylation by Prolonged Treatment with TroglitazoneJournal of Biological Chemistry, 279
N. Marx, G. Sukhova, C. Murphy, P. Libby, J. Plutzky (1998)
Macrophages in Human Atheroma Contain PPARγ: Differentiation-Dependent Peroxisomal Proliferator-Activated Receptor γ (PPARγ) Expression and Reduction of MMP-9 Activity through PPARγ Activation in Mononuclear Phagocytes in VitroAmerican Journal of Pathology, 153
P. Tontonoz, L. Nagy, J. Alvarez, V. Thomazy, R. Evans (1998)
PPARγ Promotes Monocyte/Macrophage Differentiation and Uptake of Oxidized LDLCell, 93
A. Collins, W. Meehan, U. Kintscher, S. Jackson, S. Wakino, Grace Noh, W. Palinski, W. Hsueh, R. Law (2001)
Troglitazone Inhibits Formation of Early Atherosclerotic Lesions in Diabetic and Nondiabetic Low Density Lipoprotein Receptor–Deficient MiceArteriosclerosis, Thrombosis, and Vascular Biology: Journal of the American Heart Association, 21
P. Delerive, F. Martin‐Nizard, G. Chinetti, F. Trottein, J. Fruchart, J. Najib, P. Duriez, B. Staels (1999)
Peroxisome proliferator-activated receptor activators inhibit thrombin-induced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway.Circulation research, 85 5
I. Issemann, S. Green (1990)
Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferatorsNature, 347
G. Chinetti, S. Lestavel, V. Bocher, A. Remaley, B. Neve, I. Torra, E. Teissier, A. Minnich, M. Jaye, N. Duverger, H. Brewer, J. Fruchart, V. Clavey, B. Staels (2001)
PPAR-α and PPAR-γ activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathwayNature Medicine, 7
Jianben Song, M. Walsh, R. Igwe, J. Ram, Mohamad Barazi, L. Dominguez, J. Sowers (1997)
Troglitazone Reduces Contraction by Inhibition of Vascular Smooth Muscle Cell Ca2+ Currents and Not Endothelial Nitric Oxide ProductionDiabetes, 46
D.H. Cho, Y.J. Choi, S.A. Jo (2004)
Nitric oxide production and regulation of endothelial nitric-oxide synthase phosphorylation by prolonged treatment with troglitazone: evidence for involvement of peroxisome proliferator-activated receptor (PPAR) β-dependent and PPARβ-independent signaling pathwaysJ Biol Chem, 279
Y. Fukunaga, H. Itoh, K. Doi, Tokuji Tanaka, J. Yamashita, T. Chun, M. Inoue, K. Masatsugu, N. Sawada, Takatoshi Saito, K. Hosoda, H. Kook, M. Ueda, K. Nakao (2001)
Thiazolidinediones, peroxisome proliferator-activated receptor gamma agonists, regulate endothelial cell growth and secretion of vasoactive peptides.Atherosclerosis, 158 1
T. Akiyama, S. Sakai, G. Lambert, C. Nicol, K. Matsusue, Satish Pimprale, Ying-Hue Lee, M. Ricote, C. Glass, H. Brewer, F. Gonzalez (2002)
Conditional Disruption of the Peroxisome Proliferator-Activated Receptor γ Gene in Mice Results in Lowered Expression of ABCA1, ABCG1, and apoE in Macrophages and Reduced Cholesterol EffluxMolecular and Cellular Biology, 22
David Kass, Marlene Rabinovitch, E. Creemers, J. Cleutjens, J. Smits, J. Daemen, Pharmacology
This Review Is Part of a Thematic Series on Matrix Metalloproteinases, Which Includes the following Articles: Matrix Metalloproteinase Inhibition after Myocardial Infarction: a New Approach to Prevent Heart Failure? Matrix Metalloproteinase: Regulation and Dysregulation in the failing Heart Matrix M
A. Chawla, W. Boisvert, Chih‐Hao Lee, B. Laffitte, Y. Barak, S. Joseph, D. Liao, L. Nagy, P. Edwards, L. Curtiss, R. Evans, P. Tontonoz (2001)
A PPARγ-LXR-ABCA1 Pathway in Macrophages Is Involved in Cholesterol Efflux and AtherogenesisMolecular Cell, 7
T. Springer (1994)
Traffic signals for lymphocyte recirculation and leukocyte emigration: The multistep paradigmCell, 76
Nikolaus Marx, Uwe Schonbeck, M. Lazar, P. Libby, J. Plutzky (1998)
Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells.Circulation research, 83 11
S. Kliewer, S. Kliewer, B. Forman, B. Blumberg, E. Ong, U. Borgmeyer, D. Mangelsdorf, K. Umesono, R. Evans (1994)
Differential expression and activation of a family of murine peroxisome proliferator-activated receptors.Proceedings of the National Academy of Sciences of the United States of America, 91 15
P. Gerber, G. Lübben, Sabine Heusler, Ayako Dodo (2003)
Effects of pioglitazone on metabolic control and blood pressure: a randomised study in patients with type 2 diabetes mellitusCurrent Medical Research and Opinion, 19
L. Fajas, D. Auboeuf, E. Raspé, K. Schoonjans, A. Lefebvre, R. Saladin, J. Najib, M. Laville, J. Fruchart, S. Deeb, A. Vidal-Puig, J. Flier, M. Briggs, B. Staels, H. Vidal, J. Auwerx (1997)
The Organization, Promoter Analysis, and Expression of the Human PPARγ Gene*The Journal of Biological Chemistry, 272
Y. Takata, Y. Kitami, Zhao-hui Yang, Michitsugu Nakamura, T. Okura, K. Hiwada (2002)
Vascular Inflammation Is Negatively Autoregulated by Interaction Between CCAAT/Enhancer-Binding Protein-&dgr; and Peroxisome Proliferator-Activated Receptor-&ggr;Circulation Research: Journal of the American Heart Association, 91
L. Fajas, J. Fruchart, J. Auwerx (1998)
PPARγ3 mRNA: a distinct PPARγ mRNA subtype transcribed from an independent promoterFEBS Letters, 438
A.J. Gilde, K.A. Lee, P.H. Willemsen (2003)
Peroxisome proliferator-activated receptor (PPAR) a and PPARβ/6, but not PPARy, modulate the expression of genes involved in cardiac lipid metabolismCirc Res, 92
R. Chakrabarti, R. Vikramadithyan, P. Misra, J. Hiriyan, Suryaprakash Raichur, R. Damarla, Cynthia Gershome, J. Suresh, R. Rajagopalan (2003)
Ragaglitazar: a novel PPARα & PPARγ agonist with potent lipid‐lowering and insulin‐sensitizing efficacy in animal modelsBritish Journal of Pharmacology, 140
D. Calnek, L. Mazzella, S. Roser, J. Roman, C. Hart (2003)
Peroxisome Proliferator-Activated Receptor &ggr; Ligands Increase Release of Nitric Oxide From Endothelial CellsArteriosclerosis, Thrombosis, and Vascular Biology: Journal of the American Heart Association, 23
P. Libby (2000)
Changing concepts of atherogenesisJournal of Internal Medicine, 247
Y. Tsai, Hyo-Jeong Kim, N. Takahashi, Hyung-Suk Kim, J. Hagaman, Jason Kim, N. Maeda (2004)
Hypertension and abnormal fat distribution but not insulin resistance in mice with P465L PPARgamma.The Journal of clinical investigation, 114 2
A. Norris, Lihong Chen, S. Fisher, I. Szanto, M. Ristow, A. Jozsi, M. Hirshman, E. Rosen, L. Goodyear, F. Gonzalez, B. Spiegelman, C. Kahn (2003)
Muscle-specific PPARgamma-deficient mice develop increased adiposity and insulin resistance but respond to thiazolidinediones.The Journal of clinical investigation, 112 4
X. Yang, Li Wang, Taosheng Chen, D. Hodge, J. Resau, L. DaSilva, W. Farrar (2000)
Activation of Human T Lymphocytes Is Inhibited by Peroxisome Proliferator-activated Receptor γ (PPARγ) AgonistsThe Journal of Biological Chemistry, 275
K. Eto, Y. Ohya, Y. Nakamura, I. Abe, M. Fujishima (2001)
Comparative actions of insulin sensitizers on ion channels in vascular smooth muscle.European journal of pharmacology, 423 1
R. Law, S. Goetze, X. Xi, S. Jackson, Y. Kawano, L. Demer, M. Fishbein, W. Meehan, W. Hsueh (2000)
Expression and Function of PPARγ in Rat and Human Vascular Smooth Muscle CellsCirculation, 101
Chengyu Jiang, A. Ting, B. Seed (1998)
PPAR-γ agonists inhibit production of monocyte inflammatory cytokinesNature, 391
Hiroyuki Koshiyama, Dai Shimono, N. Kuwamura, Jun Minamikawa, Yoshio Nakamura (2001)
Rapid communication: inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes.The Journal of clinical endocrinology and metabolism, 86 7
S. Wakino, U. Kintscher, Sarah Kim, F. Yin, W. Hsueh, R. Law (2000)
Peroxisome Proliferator-activated Receptor γ Ligands Inhibit Retinoblastoma Phosphorylation and G1 → S Transition in Vascular Smooth Muscle Cells*The Journal of Biological Chemistry, 275
J. Nolan, B. Ludvik, P. Beerdsen, Mary Joyce, J. Olefsky (1994)
Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone.The New England journal of medicine, 331 18
S. Bennett, A. Agrawal, H. Elasha, M. Heise, N. Jones, M. Walker, John Wilding (2004)
Rosiglitazone improves insulin sensitivity, glucose tolerance and ambulatory blood pressure in subjects with impaired glucose toleranceDiabetic Medicine, 21
J. Sidhu, D. Cowan, J. Kaski (2003)
The effects of rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, on markers of endothelial cell activation, C-reactive protein, and fibrinogen levels in non-diabetic coronary artery disease patients.Journal of the American College of Cardiology, 42 10
J. Plutzky (2003)
The vascular biology of atherosclerosis.The American journal of medicine, 115 Suppl 8A
Y. Nakamura, Y. Ohya, U. Onaka, K. Fujii, I. Abe, M. Fujishima (1998)
Inhibitory action of insulin‐sensitizing agents on calcium channels in smooth muscle cells from resistance arteries of guinea‐pigBritish Journal of Pharmacology, 123
M.N. Ghazzi, J.E. Perez, T.K. Antonucci (1997)
Cardiac and glycemie benefits of troglitazone treatment in NIDDM: the Troglitazone Study GroupDiabetes, 46
A. Sugawara, K. Takeuchi, A. Uruno, Y. Ikeda, S. Arima, M. Kudo, Kazunori Sato, Y. Taniyama, S. Ito (2001)
Transcriptional Suppression of Type 1 Angiotensin II Receptor Gene Expression by Peroxisome Proliferator-Activated Receptor-γ in Vascular Smooth Muscle Cells.Endocrinology, 142 7
Lisa Tannock, P. Little, C. Tsoi, P. Barrett, T. Wight, A. Chait (2004)
Thiazolidinediones reduce the LDL binding affinity of non-human primate vascular cell proteoglycansDiabetologia, 47
A. Gilde, K. Lee, P. Willemsen, G. Chinetti, F. Leij, G. Vusse, B. Staels, M. Bilsen (2003)
Peroxisome Proliferator-Activated Receptor (PPAR) &agr; and PPAR&bgr;/&dgr;, but not PPAR&ggr;, Modulate the Expression of Genes Involved in Cardiac Lipid MetabolismCirculation Research: Journal of the American Heart Association, 92
M. Ghazzi, Julio Pérez, T. Antonucci, J. Driscoll, Saling Huang, B. Faja, R. Whitcomb (1997)
Cardiac and Glycemic Benefits of Troglitazone Treatment in NIDDMDiabetes, 46
Chien-ping Liang, Seongah Han, H. Okamoto, Ronald Carnemolla, I. Tabas, D. Accili, A. Tall (2004)
Increased CD36 protein as a response to defective insulin signaling in macrophages.The Journal of clinical investigation, 113 5
Cardiovascular diseases are the leading cause of morbidity and mortality in the US. Proper management and/ or prevention of atherosclerosis and hypertension, two complex and chronic disorders, would significantly reduce the risk for cardiovascular events such as myocardial infarction and stroke, but this requires an understanding of the mechanisms underlying their development and progression. Whereas a great deal has been learned and applied toward the management of these disorders, especially hypertension, morbidity and mortality remains unacceptably high, most likely because there are disease-causing mechanisms that have yet to be fully recognized. Understanding these disease mechanisms is necessary so that novel management strategies can be developed. One of these novel mechanisms centers on peroxisome proliferator-activated receptor (PPAR)-β. PPAR-β is a member of the nuclear receptor superfamily of ligand-activated transcription factors known to play a role in glucose homeostasis and adipocyte differentiation and, more recently, has been shown to have anti-inflammatory, antiatherogenic, and antihypertensive effects. Thiazolidinediones, a class of drugs used in the treatment of type 2 diabetes mellitus, are high-affinity ligands for PPAR-β. In this review, the anti-inflammatory, anti-atherosclerotic, and anti-hypertensive mechanisms by which PPAR-β and its agonists are thought to exert protective effects on the cardiovascular system are discussed. Ongoing clinical trials using PPAR-β activators for the management of cardiovascular diseases, especially in patients with type 2 diabetes mellitus, are summarized.
American Journal of Cardiovascular Drugs – Springer Journals
Published: Aug 20, 2012
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.